Multivariate analysis of 36-month disease progression/relapse in a Cox model
Variable . | No. evaluable . | Hazard ratio of relapse (95% CI)* . | P (overall) contrast† . |
|---|---|---|---|
| Transplantation group (main study variable) | |||
| Standard myeloablative conditioning‡ | 621 | (1) | |
| Reduced-intensity conditioning | 215 | 1.64 (1.2-2.2) | .001 |
| Response to AML-type chemotherapy | (< .001) | ||
| First complete remission‡ | 276 | (1) | |
| Untreated | 235 | 1.2 (0.5-2.3) | .48 |
| Treated, but not in CR1 | 241 | 2.1 (1.1-3.8) | .025 |
| Risk (or disease phase) | (.001) | ||
| Early stage‡ | 365 | (1) | |
| Advanced stage | 311 | 2.2 (1.2-4.1) | .01 |
| Cytogenetics§ | (< .001) | ||
| Nonpoor risk‡ | 122 | (1) | |
| Poor risk | 188 | 2.4 (1.5-3.8) | .001 |
Variable . | No. evaluable . | Hazard ratio of relapse (95% CI)* . | P (overall) contrast† . |
|---|---|---|---|
| Transplantation group (main study variable) | |||
| Standard myeloablative conditioning‡ | 621 | (1) | |
| Reduced-intensity conditioning | 215 | 1.64 (1.2-2.2) | .001 |
| Response to AML-type chemotherapy | (< .001) | ||
| First complete remission‡ | 276 | (1) | |
| Untreated | 235 | 1.2 (0.5-2.3) | .48 |
| Treated, but not in CR1 | 241 | 2.1 (1.1-3.8) | .025 |
| Risk (or disease phase) | (.001) | ||
| Early stage‡ | 365 | (1) | |
| Advanced stage | 311 | 2.2 (1.2-4.1) | .01 |
| Cytogenetics§ | (< .001) | ||
| Nonpoor risk‡ | 122 | (1) | |
| Poor risk | 188 | 2.4 (1.5-3.8) | .001 |
Other variables with a nonsignificant trend toward increasing relapse (P = .06-.1): (1) pharmacologic GVHD prophylaxis with ATG or alemtuzumab (0.10); and (2) interval from diagnosis to transplantation other than 3 and 6 months (P = .1).
A hazard ratio less than 1.0 indicates that the variable leads to a reduction of disease relapse, while a value above 1.0 indicates that it leads to an increase in relapse.
Some risk factors in the Cox model contain a category for “unknown” to avoid loss of information; the overall P value between brackets denotes the P value of the complete risk factor; the individual P values denote the P values of the given contrasts to the reference category. For clarity, the “unknown” categories as well as the nonsignificant risk factors have been omitted from the table.
Reference group.
See “Patient and transplantation characteristics and definitions” for details.